注射用丹参多酚酸治疗进展性脑梗死效果观察

Effect of salvianolate injection in progressive cerebral infarction

目的 观察注射用丹参多酚酸治疗进展性脑梗死的效果及安全性.方法 将110例进展性脑梗死患者按随机数字表法分成常规治疗组（36例）、依达拉奉组（36例）和丹参多酚酸组（38例）.常规治疗组给予抗血小板聚集,改善循环,脑保护剂等常规治疗,依达拉奉组在常规治疗组基础上加用依达拉奉注射液治疗,丹参多酚酸组在常规治疗组基础上加用注射用丹参多酚酸治疗,疗程14 d.观察治疗前及治疗14 d后3组患者美国国立卫生研究院卒中量表（NIHSS）评分、Barthel指数（BI）评分、高敏C反应蛋白（hs-CRP）含量及临床疗效,并监测不良反应.结果 治疗后,常规治疗组NIHSS评分、BI评分及hs-CRP水平分别为（8.2±2.5）分、（47±8）分,（6.9±0.9） mag/L;依达拉奉组分别为（5.5±2.4）分、（59±9）分、（4.8±0.7） mg/L;丹参多酚酸组分别为（5.2±2.4）分、（60±9）分、（4.7±0.7） mg/L.依达拉奉组及丹参多酚酸组与常规治疗组比较NIHSS评分、BI评分、hs-CRP差异均有统计学意义（均P＜0.05）,丹参多酚酸组与依达拉奉组比较差异均无统计学意义（均P ＞0.05）.丹参多酚酸组和依达拉奉组总有效率均高于常规治疗组[69.4％（25/36）和71.1％（27/38）比41.7％ （15/36）]（P＜0.01）,而丹参多酚酸组和依达拉奉组间差异无统计学意义（P＞0.05）.3组患者治疗过程中均无不良反应发生.结论 注射用丹参多酚酸治疗进展性脑梗死可以达到与依达拉奉注射液同等疗效.

Objective To observe the effect of salvianolate injection in treatment of progressive cerebral infarction.Methods One hundred and ten patients with progressive cerebral infarction were randomly divided into conventional treatment group （36 cases） receiving conventional treatment including antiplatelet aggregation,circulation improvement and cerebral protection;edaravone group （36 cases） had edaravone injection in addition to conventional treatment;salvianolate group （38 cases） had salvianolate injection in addition to conventional treatment.Before and 14 days after treatment,the National Institute of Health stroke scale （NIHSS） score,Barthel index （BI） score and high sensitive C reactive protein （hs-CRP） were assessed;the clinical efficacy was evaluated and the adverse reactions were observed.Results After treatment,the NIHSS score,BI score and hs-CRP were （8.2 ± 2.5） scores,（47 ± 8） scores and （6.9 ± 0.9） mg/L in conventional treatment group;they were （5.5 ±2.4） scores,（59 ±9） scores and （4.8 ±0.7） mg/L in edaravone group;they were （5.2 ±2.4） scores,（60±9） scores and （4.7 ± 0.7） mg/L in salvianolate group.The NIHSS score,BI score and hs-CRP in edaravone group and salvianolate group were all significantly different compared with those in conventional treatment group （all P 〈 0.05）.The total effective rate of salvianolate and edaravone group was significantly higher than that of conventional treatment group [69.4% （25/36）,71.1% （27/38） vs 41.7% （15/36）].No adverse reactions occurred in all three groups during treatment.Conclusion Salvianolate injection is as safe and effective as edaravone injection treating progressive cerebral infarction.